GI
CRSP icon

GAMMA Investing’s CRISPR Therapeutics CRSP Stock Holding History

GAMMA Investing’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.4K Buy
649
+36
+6% +$1.9K ﹤0.01% 2533
2026
Q1 		$29.2K Buy
613
+247
+67% +$13K ﹤0.01% 2515
2025
Q4 		$19.2K Buy
366
+84
+30% +$5.03K ﹤0.01% 2642
2025
Q3 		$18.3K Buy
+282
New +$16.2K ﹤0.01% 2559
2025
Q2 		– Sell
-126
Closed -$4.29K – 3795
2025
Q1 		$4.29K Buy
126
+74
+142% +$3.14K ﹤0.01% 3143
2024
Q4 		$2.05K Sell
52
-6
-10% -$283 ﹤0.01% 3210
2024
Q3 		$2.73K Buy
58
+3
+5% +$152 ﹤0.01% 2967
2024
Q2 		$2.97K Buy
55
+5
+10% +$289 ﹤0.01% 2754
2024
Q1 		$3.41K Buy
50
+20
+67% +$1.43K ﹤0.01% 2562
2023
Q4 		$1.89K Buy
+30
New +$1.66K ﹤0.01% 2594

Other funds holding CRSP

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SC
Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return
CIC
Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $900M AUM
BIP
Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
LIM
Leavell Investment Management Mobile, Alabama $2.74B AUM 26.51% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

GAMMA Investing's CRSP Position: Q2 2026 in Review

GAMMA Investing increased its CRISPR Therapeutics (CRSP) stake by 5.9% in Q2 2026, buying an estimated $1.9K and bringing the position to 649 shares worth $35.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2533.

GAMMA Investing first reported a position in CRSP in Q4 2023 and has held it in 10 quarters since. 97 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • GAMMA Investing held 649 shares of CRISPR Therapeutics worth $35.4K as of Q2 2026.
  • GAMMA Investing bought 36 CRISPR Therapeutics shares in Q2 2026, an estimated $1.9K.
  • CRISPR Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2533 holding.
  • GAMMA Investing first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • 97 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.